by Brad Dunn | Jan 21, 2021
Elizabeth Berry-Kravis, MD, PhD, co-director of the Molecular Diagnostics Section of the Genetic Laboratory at Rush Medical College in Chicago, describes different treatment options for Niemann-Pick Type C (NPC). NPC is a disabling neurogenetic disorder that...
by Brad Dunn | Jan 20, 2021
Ally Roets and her son Sam — who was diagnosed with infantile-onset facioscapulohumeral muscular dystrophy (FSHD) when he was age 6 — talk about what they’ve learned through their journey, including the misconceptions about the disease. FSHD is a rare disabling...
by Brad Dunn | Jan 20, 2021
Dr. Anna Sureda, Head of the Onco-Hematology Service at Blood Cell Barcelona, discusses the results of the ECHELON-1 study of brentuximab vedotin as a frontline treatment for late-stage Hodgkin lymphoma. The study, which concluded in 2017, found a significant...
by Brad Dunn | Jan 19, 2021
Elizabeth Thompson, PhD at Horizon Therapeutics shares details about Tepezza for treating thyroid eye disease (TED), a rare autoimmune disease causing permanent facial disfigurement severely affecting patients’ quality of life and daily function. The disease...
by Brad Dunn | Jan 18, 2021
Elizabeth Berry-Kravis, MD, PhD, co-director of the Molecular Diagnostics Section of the Genetic Laboratory at Rush Medical College in Chicago, discusses the process of diagnosing Niemann-Pick Type C (NPC). NPC is a disabling neurogenetic disorder that has been...
